Table 4. Results of test sessions 1 and 2.
| Group: | all | INA | DOPA | SUL | Group effect |
|---|---|---|---|---|---|
| Test session 1 (day 2) | |||||
| EXPECT score preT1 (0–10) | 6.5 ± 0.2 | 6.8 ± 0.3 | 6.6 ± 0.2 | 6.1 ± 0.3 | F = 1.69, p = 0.19, ηp2 = 0.02 |
| EXPECT score change from preCOND to preT1 | 0.7 ± 0.1 | 0.7 ± 0.2 | 0.8 ± 0.3 | 0.5 ± 0.3 | F = 0.38, p = 0.68, ηp2 = 0.01 |
| EFFECT score (0–10) | 4.4 ± 0.2 | 4.9 ± 0.3 | 4.4 ± 0.3 | 3.8 ± 0.4 | F = 2.35, p = 0.10, ηp2 = 0.03 |
| Pain rating at control (VAS) | 52.3 ± 1.3 | 50.7 ± 2.3 | 54.0 ± 2.2 | 52 ± 2.5 | F = 0.50, p = 0.60, ηp2 = 0.01 |
| Pain rating at placebo (VAS) | 49.1 ± 1.4 | 46.8 ± 2.6 | 50.3 ± 2.1 | 50.1 ± 2.4 | F = 0.69, p = 0.51, ηp2 = 0.01 |
| Placebo analgesia (VAS control–VAS placebo) | 3.2 ± 1.1 | 3.9 ± 1.8 | 3.7 ± 2.1 | 1.9 ± 1.7 | F = 0.35, p = 0.71, ηp2 < 0.01 |
| Placebo first | 50.0% | 51.0% | 43.4% | 56.0% | - |
| Test session 2 (day 8) | |||||
| EXPECT score preT2 (0–10) | 6.0 ± 0.2 | 6.2 ± 0.3 | 6.0 ± 0.3 | 5.7 ± 0.3 | F = 0.94, p = 0.39, ηp2 = 0.01 |
| EXPECT score change from preCOND to preT2 | 0.1 ± 0.2 | 0.2 ± 0.2 | 0.3 ± 0.3 | −0.04 ± 0.3 | F = 0.32, p = 0.72, ηp2 < 0.01 |
| EFFECT score (0–10) | 4.1 ± 0.2 | 4.6 ± 0.3 | 3.9 ± 0.4 | 3.9 ± 0.4 | F = 1.41, p = 0.25, ηp2 = 0.02 |
| Pain rating at control (VAS) | 45.9 ± 1.4 | 48.0 ± 2.3 | 46.0 ± 2.3 | 43.7 ± 2.7 | F = 0.74, p = 0.48, ηp2 = 0.01 |
| Pain rating at placebo (VAS) | 43.9 ± 1.4 | 43.5 ± 2.5 | 45.0 ± 2.1 | 43.0 ± 2.8 | F = 0.18, p = 0.84, ηp2 < 0.01 |
| Placebo analgesia (VAS control–VAS placebo) | 2.1 ± 1.2 | 4.4 ± 1.9 | 1.0 ± 2.1 | 0.7 ± 2.0 | F = 1.05, p = 0.35, ηp2 = 0.01 |
| Placebo first | 49.0% | 43.1% | 49.1% | 55.1% | - |
Metrics are given as mean ± SEM. Group differences are calculated with ANOVAs.